

101018617

8


## PATENT COOPERATION TREATY

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

TECH CENTER 1600/2900





Applicant's or agent's file reference PC5953/20132	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IB01/00026	International filing date (day/month/year) 11/01/2001	Priority date (day/month/year) 25/01/2000
International Patent Classification (IPC) or national classification and IPC C07C59/125		
Applicant WARNER-LAMBERT COMPANY et al.		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 4 sheets, including this cover sheet.
  - ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 10/05/2001	Date of completion of this report 27.03.2002
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Janus, S Telephone No. +49 89 2399 8333 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IB01/00026

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-38 as originally filed

**Claims, No.:**

1-51 as originally filed

**Drawings, sheets:**

1/27-27/27 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB01/00026

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims 28-41
	No:	Claims 1-27, 42-51
Inventive step (IS)	Yes:	Claims
	No:	Claims 28-41
Industrial applicability (IA)	Yes:	Claims 1-45, 48
	No:	Claims 46, 47, 49-51

- 2. Citations and explanations  
see separate sheet**

**Concerning Section V**

1. WO-A-99/30704 (D1) discloses (see in particular example I) the use of a pharmaceutical composition comprising the calcium salt of atorvastatin and the calcium salt of 6, 6'-oxybis-(2,2-dimethylhexanoic acid), also named CI-1027. It is also said in D1 (see p. 7, line 8) that the compounds of formula III (to which CI-1027 belongs) may occur as hydrates or solvates.

It is therefore considered that the skilled person would have, after reading D1, seriously contemplated preparing the present compounds of formula (II), in all possible crystal forms.

For these reasons, the subject-matter of present claims 1-27 and 42-51 is regarded as anticipated by D1 (Art. 33.2 PCT).

2. D1 does not specify how said compound CI-1027 is actually prepared. However, D1 does describe generally (see p. 7, lines 4-6) the preparation of "pharmaceutically acceptable" salts by neutralisation of the free acid in a co-solvent, concentration (i.e. solvent evaporation) being mentioned as a possible isolation procedure. The process claimed in present claims is therefore regarded as one of very few possibilities the skilled person would have selected from in order to prepare the compounds of D1, without having to exercise any sort of inventive activity.

The subject-matter of present claims 28-41 must therefore be regarded as lacking inventive step.

3. For the assessment of the present claims 46, 47 and 49-51 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>PC5953/20132</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/IB 01/ 00026</b>	International filing date (day/month/year) <b>11/01/2001</b>	(Earliest) Priority Date (day/month/year) <b>25/01/2000</b>
Applicant  <b>WARNER-LAMBERT COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.  
☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☒ **None of the figures.**

Express Mail No. EF378134374US

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 01/00026

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 46, 47 and 49-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

/IB 01/00026

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C59/125 A61K31/19 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 30704 A (WARNER LAMBERT CO ;BISGAIER CHARLES LARRY (US); NEWTON ROGER SCHOF) 24 June 1999 (1999-06-24) page 7, line 4 - line 8; example I	1-51
A	WO 96 30328 A (WARNER LAMBERT CO) 3 October 1996 (1996-10-03) page 11, line 1; claim 9; example 1	1-51
A	& US 5 648 387 A 15 July 1997 (1997-07-15) cited in the application	

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 March 2001

Date of mailing of the international search report

28.03.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Janus, S

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No


PCT/IB 01/00026

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9930704 A	24-06-1999	AU 1591599 A BR 9813542 A EP 1045691 A NO 20002966 A ZA 9811348 A	05-07-1999 10-10-2000 25-10-2000 09-06-2000 14-06-1999
WO 9630328 A	03-10-1996	US 5648387 A AT 192732 T AU 692359 B AU 4776896 A BG 101993 A CA 2215233 A CN 1182415 A CZ 9702922 A DE 69608268 D DE 69608268 T EP 0820428 A ES 2148733 T FI 973713 A HU 9801825 A JP 11502532 T NO 974397 A NZ 302170 A PL 322407 A PT 820428 T SI 820428 T SK 128697 A US 5750569 A US 5783600 A US 5756544 A ZA 9602275 A	15-07-1997 15-05-2000 04-06-1998 16-10-1996 29-05-1998 03-10-1996 20-05-1998 14-10-1998 15-06-2000 09-11-2000 28-01-1998 16-10-2000 24-09-1997 28-12-1998 02-03-1999 20-11-1997 29-04-1999 19-01-1998 29-09-2000 31-08-2000 11-02-1999 12-05-1998 21-07-1998 26-05-1998 30-09-1996



1/27

FIG. 1



2/27

FIG. 1A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.760	13.0648	5106	100.0	1497	100.0	0.234
2	8.183	10.7953	1743	34.1	435	29.1	0.200
3	8.560	10.3207	1866	36.5	543	36.3	0.233
4	9.239	9.5638	234	4.6	29	1.9	0.096
5	9.760	9.0546	972	19.0	220	14.7	0.181
6	10.569	8.3634	156	3.1	12	0.8	0.061
7	11.141	7.9353	178	3.5	29	1.9	0.130
8	13.760	6.4304	266	5.2	46	3.1	0.138
9	15.599	5.6761	338	6.6	63	4.2	0.148
10	16.740	5.2917	433	8.5	64	4.3	0.118
11	17.420	5.0866	1890	37.0	689	46.0	0.291
12	20.639	4.3000	523	10.2	128	8.5	0.196
13	21.391	4.1505	188	3.7	20	1.3	0.085
14	22.139	4.0119	445	8.7	74	4.9	0.132
15	31.559	2.8326	270	5.3	24	1.6	0.070

3/27

FIG. 2





FIG. 2A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.899	12.8028	13186	100.0	3025	100.0	0.184
2	8.261	10.6945	5221	39.6	931	30.8	0.143
3	8.838	9.9969	2057	15.6	482	15.9	0.187
4	11.061	7.9927	785	6.0	160	5.3	0.163
5	12.100	7.3086	1355	10.3	150	4.9	0.088
6	13.619	6.4964	450	3.4	89	2.9	0.157
7	17.677	5.0132	753	5.7	126	4.2	0.134
8	18.180	4.8755	2011	15.3	588	19.4	0.234
9	20.840	4.2588	439	3.3	40	1.3	0.072
10	21.334	4.1615	427	3.2	67	2.2	0.125

4/27

5/27

FIG. 3




6/27

FIG. 3A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.959	12.6918	8224	100.0	2809	100.0	0.273
2	8.381	10.5414	2375	28.9	732	26.0	0.246
3	8.701	10.1544	2107	25.6	742	26.4	0.282
4	9.383	9.4176	328	4.0	25	0.9	0.060
5	9.941	8.8906	1160	14.1	356	12.7	0.245
6	13.975	6.3317	330	4.0	26	0.9	0.062
7	15.778	5.6120	244	3.0	38	1.3	0.121
8	16.920	5.2357	597	7.3	213	7.6	0.284
9	17.540	5.0521	2206	26.8	729	25.9	0.264
10	20.799	4.2672	407	4.9	71	2.5	0.138
11	22.261	3.9902	563	6.8	107	3.8	0.152

7/27

FIG. 4



8/27


FIG. 4A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.896	12.8072	11991	100.0	2593	100.0	0.173
2	8.339	10.5940	2046	17.1	334	12.9	0.131
3	9.219	9.5853	1438	12.0	281	10.8	0.156
4	10.280	8.5979	632	5.3	180	6.9	0.227
5	11.320	7.8105	1079	9.0	322	12.4	0.238
6	15.800	5.6044	463	3.9	59	2.3	0.102
7	16.741	5.2913	432	3.6	38	1.4	0.069
8	18.160	4.8809	1260	10.5	599	23.1	0.380
9	18.702	4.7408	700	5.8	184	7.1	0.210
10	19.816	4.4766	589	4.9	94	3.6	0.127
11	21.724	4.0876	510	4.3	96	3.7	0.150



9/27

FIG. 5




10/27

FIG. 5A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.901	12.7988	10206	100.0	2683	100.0	0.210
2	8.360	10.5679	2545	24.9	524	19.5	0.164
3	8.680	10.1792	1459	14.3	359	13.4	0.197
4	9.279	9.5230	580	5.7	91	3.4	0.125
5	9.879	8.9456	794	7.8	143	5.3	0.143
6	11.321	7.8094	577	5.7	97	3.6	0.133
7	15.780	5.6113	523	5.1	95	3.5	0.144
8	17.541	5.0519	1710	16.8	418	15.6	0.195
9	18.702	4.7408	459	4.5	116	4.3	0.201
10	19.877	4.4631	403	3.9	67	2.5	0.133

11/27

FIG. 6




12/27

FIG. 6A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.899	12.8025	12371	100.0	3495	100.0	0.226
2	7.843	11.2637	4815	38.9	1119	32.0	0.186
3	8.661	10.2009	1709	13.8	357	10.2	0.167
4	11.359	7.7833	771	6.2	141	4.0	0.146
5	12.300	7.1900	752	6.1	127	3.6	0.135
6	13.100	6.7528	517	4.2	37	1.0	0.057
7	18.262	4.8540	1945	15.7	596	17.1	0.245
8	20.721	4.2832	828	6.7	279	8.0	0.269
9	21.740	4.0847	573	4.6	146	4.2	0.203

13/27

FIG. 7




14/27

FIG. 7A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.939	12.7278	9980	100.0	2717	100.0	0.218
2	8.381	10.5414	2850	28.6	790	29.1	0.222
3	8.640	10.2253	2267	22.7	772	28.4	0.272
4	9.419	9.3815	487	4.9	32	1.2	0.051
5	9.840	8.9812	1288	12.9	255	9.4	0.158
6	13.940	6.3476	374	3.7	56	2.0	0.118
7	15.741	5.6253	450	4.5	45	1.6	0.079
8	16.861	5.2539	580	5.8	192	7.0	0.264
	17.560	5.0464	2604	26.1	846	31.1	0.260
10	20.743	4.2787	508	5.1	73	2.7	0.114
11	22.321	3.9796	542	5.4	156	5.7	0.229

15/27

FIG. 8



16/27


FIG. 8A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.918	12.7674	10028	100.0	2562	100.0	0.204
2	8.000	11.0427	3984	39.7	800	31.2	0.161
3	8.619	10.2506	1619	16.1	346	13.5	0.171
4	11.338	7.7981	658	6.6	68	2.6	0.082
5	11.718	7.5459	236	2.4	28	1.1	0.093
6	12.241	7.2243	761	7.6	131	5.1	0.138
7	15.382	5.7557	610	6.1	107	4.2	0.140
8	18.162	4.8803	1937	19.3	441	17.2	0.182
9	20.779	4.2713	853	8.5	222	8.6	0.208



17/27

FIG. 9




18/27

FIG. 9A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.877	12.8422	8063	100.0	2195	100.0	0.218
2	8.330	10.6062	2501	31.0	800	36.4	0.256
3	8.581	10.2965	1898	23.5	514	23.4	0.217
4	9.356	9.4446	432	5.4	45	2.0	0.082
5	9.799	9.0191	1064	13.2	275	12.5	0.207
6	13.864	6.3821	293	3.6	58	2.6	0.158
7	15.721	5.6322	312	3.9	67	3.0	0.170
8	17.480	5.0693	2458	30.5	898	40.9	0.292
9	20.818	4.2633	299	3.7	67	3.0	0.178
10	22.280	3.9869	416	5.2	106	4.8	0.202

19/27

FIG. 10




20/27

FIG. 10A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	7.060	12.5101	19609	100.0	4796	100.0	0.196
2	9.078	9.7332	3027	15.4	567	11.8	0.150
3	11.100	7.9644	924	4.7	164	3.4	0.142
4	16.361	5.4135	554	2.8	76	1.6	0.109
5	18.040	4.9133	2276	11.6	456	9.5	0.160
6	18.820	4.7112	1303	6.6	385	8.0	0.236
7	19.922	4.4532	1886	9.6	457	9.5	0.193
8	21.560	4.1183	853	4.4	205	4.3	0.191
9	22.281	3.9867	343	1.7	37	0.8	0.086
10	23.521	3.7793	450	2.3	107	2.2	0.189

21/27

FIG. 11




22/27

FIG. 11A

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	7.018	12.5854	9344	100.0	2618	100.0	0.224
2	8.432	10.4775	2599	27.8	676	25.8	0.208
3	8.722	10.1302	2091	22.4	697	26.6	0.266
4	9.499	9.3030	378	4.0	33	1.2	0.069
5	9.980	8.8560	1243	13.3	337	12.9	0.217
6	14.000	6.3206	390	4.2	64	2.4	0.130
7	15.861	5.5830	550	5.9	46	1.7	0.066
8	16.881	5.2479	595	6.4	115	4.4	0.154
9	17.622	5.0287	3006	32.2	1053	40.2	0.280
10	20.918	4.2431	718	7.7	113	4.3	0.126
11	21.641	4.1031	318	3.4	44	1.7	0.110
12	22.380	3.9693	573	6.1	144	5.5	0.201

23/27



24/27





FIG. 13

a-SOLVENT FREE CRYSTALLINE FORM FROM METHYL ALCOHOL SOLVATE  
b1-SOLVENT FREE CRYSTALLINE FORM FROM ETHYL ALCOHOL SOLVATE (LAB SCALE)  
b2-SOLVENT FREE CRYSTALLINE FORM FROM ETHYL ALCOHOL SOLVATE (PILOT SCALE)  
c-SOLVENT FREE CRYSTALLINE FORM FROM 1-PROPYL ALCOHOL SOLVATE  
d-SOLVENT FREE CRYSTALLINE FORM FROM 2-PROPYL ALCOHOL SOLVATE  
e-SOLVENT FREE CRYSTALLINE FORM FROM 1-BUTYL ALCOHOL SOLVATE




25/27

FIG. 14



26/27

FIG. 15



27/27

FIG. 15A

#	2-THETA	d(A)	PEAK	P%	AREA	AREA%	FWHM
1	7.259	12.1686	9283	100	2482	100	0.214
2	8.739	10.1100	4191	45.1	603	24.3	0.115
3	9.386	8.9628	967	10.4	161	6.5	0.133
4	11.659	7.5838	430	4.6	49	1.9	0.089
5	13.955	6.3408	305	3.3	58	2.3	0.151
6	14.220	6.2233	326	3.5	73	2.9	0.178
7	15.387	5.7537	278	3.0	19	0.7	0.053
8	16.461	5.3806	986	10.6	187	7.5	0.152
9	17.361	5.1039	1490	16.1	348	14.0	0.187
10	18.063	4.9069	1284	13.8	323	13.0	0.201
11	19.302	4.5947	871	9.4	166	6.7	0.152
12	19.862	4.4664	686	7.4	142	5.7	0.166
13	20.200	4.3923	457	4.9	103	4.1	0.179
14	21.178	4.1918	656	7.1	97	3.9	0.117
15	21.641	4.1031	167	1.8	6	0.2	0.029
16	22.300	3.9833	794	8.6	192	7.7	0.193
17	23.218	3.8278	247	2.7	23	0.9	0.071
18	24.100	3.6897	183	2.0	34	1.3	0.145
19	25.481	3.4928	487	5.2	141	5.7	0.231
20	28.800	3.0974	134	1.4	14	0.6	0.083
21	29.297	3.0459	259	2.8	28	1.1	0.084
22	30.700	2.9099	287	3.1	20	0.8	0.055